Bill Sponsor
Senate Bill 1521
117th Congress(2021-2022)
Gabriella Miller Kids First Research Act 2.0
Introduced
Introduced
Introduced in Senate on Apr 29, 2021
Overview
Text
Sponsor
Introduced
Apr 29, 2021
Latest Action
Apr 29, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1521
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Virginia
Republican
Louisiana
Democrat
Minnesota
Democrat
New Mexico
Democrat
Pennsylvania
Democrat
Virginia
Democrat
West Virginia
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Gabriella Miller Kids First Research Act 2.0

This bill modifies funding for a pediatric disease research initiative within the National Institutes of Health (NIH).

Currently, this initiative receives funding through FY2023 from the 10-Year Pediatric Research Initiative Fund.

This bill directs certain penalties assessed by the Securities and Exchange Commission against pharmaceutical companies for specified violations to that fund. In making allocations from the fund, the NIH must prioritize pediatric research that does not duplicate existing research activities.

Text (1)
April 29, 2021
Actions (2)
04/29/2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2365)
04/29/2021
Introduced in Senate
Public Record
Record Updated
Mar 8, 2023 8:12:44 PM